Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
This grant funds collaborative teams to develop and clinically test new or repurposed drugs that cross the blood-brain barrier to improve adult glioblastoma treatment.
Browse similar grants
Funder: National Institutes of Health
Due Dates: January 11, 2027 (Application deadline)
Funding Amounts: $700,000 award ceiling; $4,400,000 estimated total funding for 4 expected awards
Summary: Supports collaborative development and early clinical testing of therapies that cross the blood-brain barrier to treat adult glioblastoma.
Key Information: Clinical trials are required; foreign organizations, non-U.S. components of U.S. organizations, and foreign components are not allowed.
Description
The National Cancer Institute (NCI) seeks research on novel therapies for adult glioblastoma (GBM) through the Glioblastoma Therapeutics Network (GTN). The program aims to develop effective agents that cross the blood-brain barrier and test them clinically, bridging the gap between late preclinical development and early Phase 0/1 clinical studies.
The network will bring together highly collaborative, cross-cutting teams capable of advancing therapeutic agents through preclinical development, investigational new drug (IND) studies, and pilot clinical studies in humans. Supported approaches include novel agents and agents or combinations approved for other indications and repurposed for GBM after appropriate preclinical studies. Successful early-stage trials would transition to later-stage trials through established NCI clinical trial mechanisms.
